Latest Janssen Pharmaceuticals Inc. Stories
Janssen Expands EXPLORER Cardiovascular Research Program to Include New, Multi-Trial, Prospective Research Program Aimed at Generating New Evidence in Treating and Preventing Cancer-Associated Blood
TITUSVILLE, N.J., May 19, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc.
93% of patients treated with INVEGA TRINZA(TM) remained relapse-free at the end of long-term maintenance trial TITUSVILLE, N.J., May 19, 2015 /PRNewswire/ -- There's a new treatment option
Findings Also Show Some Patients Discontinue Use of Other Blood-Glucose-Lowering Medications after Initiation of INVOKANA® RARITAN, N.J., May 18, 2015 /PRNewswire/ -- Janssen Pharmaceuticals,
Results Add to Findings from Ongoing Five-Year Post-Marketing Safety Program of XARELTO® Use in Clinical Practice NATIONAL HARBOR, Md., May 15, 2015 /PRNewswire/ -- New data from an ongoing
VENTURE-AF, the First Global, Prospective, Randomized Trial of Any Novel Oral Anticoagulant in this Setting, Presented as Late-Breaking Clinical Trial RARITAN, N.J., May 14, 2015 /PRNewswire/
TITUSVILLE, N.J., May 11, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced today that the U.S.
New research shows marked differences between Hispanic and non-Hispanic type 2 diabetes patients in disease perceptions and management approaches, highlighting need for tailored education among patients
Trial is the first to study schizophrenia treatment within the context of many real-world issues faced by patients with schizophrenia TITUSVILLE, N.J., April 15, 2015 /PRNewswire/ -- A study
TITUSVILLE, N.J., April 2, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (JPI) today announced it has completed the divestiture of its U.S.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.